DistantNews
Support us
🇮🇩 Indonesia /Economy & Trade

Novo Nordisk sues Eli Lilly over 'misleading' drug ads

From Tempo · () Indonesian

Translated from Indonesian, summarized and contextualized by DistantNews.

At a glance

News Sources not specified New plan
  • Novo Nordisk is suing Eli Lilly in a US court for allegedly using outdated studies in advertisements comparing their respective weight-loss and diabetes drugs.
  • The Danish company claims Eli Lilly's ads deceptively present results as proof of superiority while omitting critical context, causing widespread confusion.
  • Novo Nordisk emphasizes the need for accurate information as new, more effective treatments become available.

Novo Nordisk, the maker of Ozempic and Wegovy, has filed a lawsuit against its main competitor, Eli Lilly, accusing the US-based company of running "false and misleading" advertising campaigns. The Danish pharmaceutical giant alleges that Eli Lilly is intentionally using outdated studies to compare higher doses of its drugs, Mounjaro and Zepbound, against lower doses of Novo Nordisk's popular GLP-1 agonist medications.

According to Novo Nordisk, Eli Lilly's advertisements "deceptively (presented) those results as proof of broad, product-level superiority while burying or omitting critical clinical context." The company's general counsel, John F. Kuckelman, stated, "As new and more effective treatment options become available, people deserve accurate information that reflects the latest scientific evidence and helps them make informed care decisions."

The lawsuit centers on an Eli Lilly campaign that Novo Nordisk claims aired during major global sporting events and on social media platforms like TikTok and Facebook, leading to "widespread confusion." The suit, filed in a US district court in New Jersey, asserts claims of breaches in fair competition laws and federal false advertising statutes. Both companies have developed synthetic GLP-1 molecules, which mimic a natural hormone to control appetite and are used to treat type 2 diabetes and aid in weight loss, generating significant revenue for both.

As new and more effective treatment options become available, people deserve accurate information that reflects the latest scientific evidence and helps them make informed care decisions.

— John F. KuckelmanNovo Nordisk's general counsel, explaining the company's stance on accurate drug advertising.
DistantNews Editorial

Originally published by Tempo in Indonesian. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.

More Stories

From Our Blog